We’re thrilled to announce that Norgine has received regulatory approval from the Therapeutics Goods Administration (TGA) to distribute DFMO, a life-changing treatment for neuroblastoma, in Australia. We are the first country outside of the U.S to receive such approval. Read more
Neuroblastoma Australia is delighted to announce that our CEO and founder, Lucy Jones, has been awarded the 2024 Consumer Engagement in Cancer Research Award. A grant of $5000 was also made to the charity in acknowledgement of the important work carried out by the charity. Read more
We need the help of our community to secure access to TWO new treatments (DFMO and Dinutuximab Beta) that could make a significant different to children with neuroblastoma. Read more
We're thrilled to welcome award winning chef and restaurateur, Jean-Christophe Novelli, as a Neuroblastoma Australia ambassador. Read more
Neuroblastoma Australia has welcomed the release of the National Childhood, Adolescent and Young Adult Cancer Roadmap, describing it as an important step forward for children and families affected by cancer. Read more
Neuroblastoma Australia is extremely disappointed the Federal Budget did not include specific funding for CAR-T Cell treatment for solid tumours - it’s a devastating omission for Australian children diagnosed with neuroblastoma. Read more
Little legend, Logan, was diagnosed with neuroblastoma as a baby. Recently, Collingwood's Nick Daicos made Logan's dream come true by running out onto the pitch with him for Daicos' 100th AFL appearance. Read more
Neuroblastoma Australia is pleased to announce that our 2026 Grant Round is now underway. In 2026, our funding will focus specifically on Immunotherapy, a rapidly evolving area of research that holds enormous promise for improving outcomes for children diagnosed with neuroblastoma. Read more
We are exceptionally proud of our world-class Scientific Advisory Board, which plays a vital role in assessing funding for proposed research projects. We are thrilled to welcome Professor Gudrun Schleiermacher as the newest member of the Board. Read more
We’re delighted to introduce our new Nursery and Newborn collection, a thoughtfully curated range of essential baby room furniture and accessories where every purchase helps support vital childhood cancer research. Read more
Neuroblastoma Awareness Week 2–9 February 2026. We are proud to launch Postcards for Purpose, our campaign to raise awareness and advocate for better treatments for children with neuroblastoma. Read more
We are delighted to announce that Neuroblastoma Australia has been awarded a 2025 CommBank Staff Foundation Community Grant. Read more
On Friday September 5, we gathered for an unforgettable evening to honour Sienna, who would have celebrated her 18th birthday this year. Read more
This September, for Childhood Cancer Awareness Month, Neuroblastoma Australia shared #30Faces — a powerful campaign sharing the stories of 30 brave children, one for each day of the month. Read more
Neuroblastoma Australia is celebrating the huge success of our very first Run2Cure Brisbane — and what an incredible debut it was! Nearly 2,000 participants ran or walked along the banks of the beautiful Brisbane River to support children with the childhood cancer, neuroblastoma. Read more
After a long campaign, we are delighted to announce that eflornithine (DFMO) has been officially listed on Australia's PBS. Cost effective access to this treatment in Australia will make a significant difference to the lives of children diagnosed with neuroblastoma, and their families. Read more
We're delighted to announce that the Medical Services Advisory Committee (MSAC) is officially recommending Dinutuximab beta (Qarziba®) in combination with chemotherapy for the treatment of primary relapsed or refractory high-risk neuroblastoma. Read more
We’d like to extend our heartfelt thanks to the amazing Kevin Apps, who has just completed an extraordinary journey—walking all the way from Melbourne to Brisbane to raise awareness and vital funds for Neuroblastoma Australia. Read more
This End of Financial Year, we're looking to raise $100,000 to support our CAR-T Cell Fighting Fund. CAR T-cell therapy is a promising new treatment that harnesses a child’s own immune system to find and destroy cancer cells. Donate today and help us change the future for children like 4-year-old Chloe. Read more
Neuroblastoma Australia is pleased to announce that DFMO is approved by the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS). Read more
Neuroblastoma Australia is urgently calling on both the Albanese Government and the Coalition to commit $10 million to bring desperately needed new treatment options to Australia for children with high-risk neuroblastoma, particularly those who have suffered relapse. Read more
We are excited to announce that registrations are now open for our very first Brisbane Run2Cure on August 10, 2025, at New Farm Park. For a limited time, save 25% on early bird sign-up! Read more
We're thrilled to announce the winners of our 2024 Grants Round. Three outstanding projects will each received $150,000 to undertake research into advancing treatments for neuroblastoma. Read more
Minister for Health, Mark Butler MP, has released a press release to confirm that DFMO will now be provided through an Extended Access Program organised by the company Norgine. This replaces the bridging funding the Federal Government provided to famililes impacted by neuroblastoma from July this year in an unprecedented move to support children with cancer. Read more
Neuroblastoma Australia issues media release following appeals to the Federal Government to provide interim funding for access to DFMO treatment for children with neuroblastoma. Read more